Aspiro Therapeutics Joins Biotechnology Innovation Organization (BIO)

Tucson, AZ / Jan. 22, 2025–Aspiro Therapeutics, a pioneering biotech company dedicated to developing advanced treatments for obstructive lung diseases, is excited to announce its membership with the Biotechnology Innovation Organization (BIO.org). By joining the world’s largest trade association representing the biotechnology industry, Aspiro reaffirms its commitment to advancing groundbreaking science and fostering collaboration across the global biotech community.

“Joining BIO.org is an important milestone for Aspiro Therapeutics,” said James Lovgren, CEO and Co-Founder of Aspiro Therapeutics. “As we work to revolutionize treatments for obstructive lung diseases, BIO provides an invaluable platform for networking, advocacy, and access to the resources we need to achieve our mission. This partnership will allow us to deepen our engagement with industry leaders, investors, and policymakers who share our passion for innovation and patient impact.”

BIO.org supports over 1,000 member companies globally, representing innovative organizations across biotechnology and life sciences. Membership offers Aspiro access to a diverse network of peers, industry-leading events like the BIO International Convention, and advocacy initiatives that drive policy solutions to support scientific advancement.

As Aspiro advances the development of its CC16-derived peptidomimetic therapies, the company looks forward to leveraging BIO’s resources to collaborate with like-minded partners and accelerate the development of transformative treatments for conditions like asthma and COPD.

“Being part of BIO aligns perfectly with our vision to bring disease-modifying therapies to patients in need,” added Lovgren. “Together, we can amplify the voice of the biotech industry and drive solutions that have a meaningful impact on health care.”

To learn more about BIO, visit www.bio.org.